- Home
- ZDAI vs VYNE Comparison
ZDAI vs VYNE Comparison
Compare ZDAI & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDAI
- VYNE
- Stock Information
- Founded
- ZDAI 2022
- VYNE 2003
- Country
- ZDAI Hong Kong
- VYNE United States
- Employees
- ZDAI N/A
- VYNE N/A
- Industry
- ZDAI General Bldg Contractors - Nonresidential Bldgs
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- ZDAI Consumer Discretionary
- VYNE Health Care
- Exchange
- ZDAI Nasdaq
- VYNE Nasdaq
- Market Cap
- ZDAI 14.8M
- VYNE 12.3M
- IPO Year
- ZDAI 2024
- VYNE 2018
- Fundamental
- Price
- ZDAI $0.39
- VYNE $0.38
- Analyst Decision
- ZDAI
- VYNE Buy
- Analyst Count
- ZDAI 0
- VYNE 2
- Target Price
- ZDAI N/A
- VYNE $8.00
- AVG Volume (30 Days)
- ZDAI 2.3M
- VYNE 1.7M
- Earning Date
- ZDAI 12-02-2025
- VYNE 11-06-2025
- Dividend Yield
- ZDAI N/A
- VYNE N/A
- EPS Growth
- ZDAI N/A
- VYNE N/A
- EPS
- ZDAI N/A
- VYNE N/A
- Revenue
- ZDAI $19,275,673.00
- VYNE $524,000.00
- Revenue This Year
- ZDAI N/A
- VYNE N/A
- Revenue Next Year
- ZDAI N/A
- VYNE N/A
- P/E Ratio
- ZDAI N/A
- VYNE N/A
- Revenue Growth
- ZDAI 43.16
- VYNE 6.29
- 52 Week Low
- ZDAI $0.36
- VYNE $0.28
- 52 Week High
- ZDAI $107.36
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- ZDAI 36.90
- VYNE 55.03
- Support Level
- ZDAI $0.45
- VYNE $0.35
- Resistance Level
- ZDAI $0.40
- VYNE $0.40
- Average True Range (ATR)
- ZDAI 0.04
- VYNE 0.03
- MACD
- ZDAI -0.00
- VYNE 0.00
- Stochastic Oscillator
- ZDAI 18.82
- VYNE 74.75
About ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.